Pure Global

Study in Patients With Advanced Solid Malignancies to Evaluate the Safety of FTL001 - Trial NCT06410092

Access comprehensive clinical trial information for NCT06410092 through Pure Global AI's free database. This Phase 1 trial is sponsored by Sound Biopharmaceuticals Ltd. and is currently Recruiting. The study focuses on Solid Tumor. Target enrollment is 44 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.

Free Database
Powered by Pure Global AI
840K+ Trials
NCT06410092
Phase 1
Recruiting
drug
Trial Details
ClinicalTrials.gov • NCT06410092
View on ClinicalTrials.gov
Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing
Study in Patients With Advanced Solid Malignancies to Evaluate the Safety of FTL001
A Phase 1, First-in-Human, Open-Label, Dose Escalation and Dose Expansion Study of FTL001 in Patients With Advanced or Metastatic Solid Tumors

Study Focus

Solid Tumor

FTL001

Interventional

drug

Sponsor & Location

Sound Biopharmaceuticals Ltd.

Beijing,Chongqing,Chengdu, China

Timeline & Enrollment

Phase 1

Jun 05, 2023

Mar 01, 2027

44 participants

Primary Outcome

Number of participants with dose-limiting toxicities (DLTs)

Summary

This is an open, multi-center, Phase I clinical study to evaluate the safety, tolerability,
 pharmacokinetics/pharmacokinetics and initial efficacy of FTL001 in patients with advanced
 and metastatic solid tumors.

ICD-10 Classifications

Malignant neoplasm: Connective and soft tissue, unspecified
Carcinoma in situ, unspecified
Malignant neoplasm: Parametrium
Malignant neoplasm of other connective and soft tissue
Malignant neoplasm: Lip, unspecified, inner aspect

Data Source

ClinicalTrials.gov

NCT06410092

Non-Device Trial